Suppr超能文献

预测异基因造血干细胞移植患者颅内出血的死亡率。

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation.

机构信息

Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.

National Clinical Research Center for Hematologic Disease, Beijing, China.

出版信息

Blood Adv. 2021 Dec 14;5(23):4910-4921. doi: 10.1182/bloodadvances.2021004349.

Abstract

Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, a total of 70 allo-HSCT patients with an ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with an ICH diagnosis were collected from 12 other medical centers during the same period, and they comprised the external validation cohort. These 2 cohorts were used to develop and validate a grading scale that enables the prediction of 30-day mortality from ICH in all-HSCT patients. Four predictors (lactate dehydrogenase level, albumin level, white blood cell count, and disease status) were retained in the multivariable logistic regression model, and a simplified grading scale (termed the LAWS score) was developed. The LAWS score was adequately calibrated (Hosmer-Lemeshow test, P > .05) in both cohorts. It had good discrimination power in both the derivation cohort (C-statistic, 0.859; 95% confidence interval, 0.776-0.945) and the external validation cohort (C-statistic, 0.795; 95% confidence interval, 0.645-0.945). The LAWS score is the first scoring system capable of predicting 30-day mortality from ICH in allo-HSCT patients. It showed good performance in identifying allo-HSCT patients at increased risk of early mortality after ICH diagnosis. We anticipate that it would help risk stratify allo-HSCT patients with ICH and facilitate future studies on developing individualized and novel interventions for patients within different LAWS risk groups.

摘要

颅内出血 (ICH) 是异基因造血干细胞移植 (allo-HSCT) 后罕见但致命的中枢神经系统并发症。然而,对于 allo-HSCT 后发生 ICH 的患者,哪些因素可预测其早期死亡率尚未得到系统研究。2008 年 1 月至 2020 年 6 月,共纳入 70 例 allo-HSCT 患者,这些患者均被诊断为 ICH,形成了推导队列。同期,从其他 12 个医疗中心共收集了 41 例 allo-HSCT 患者,这些患者被诊断为 ICH,构成外部验证队列。本研究使用这 2 个队列开发并验证了一个分级量表,该量表可预测 allo-HSCT 患者 ICH 后的 30 天死亡率。多变量逻辑回归模型保留了 4 个预测因素(乳酸脱氢酶水平、白蛋白水平、白细胞计数和疾病状态),并建立了简化分级量表(称为 LAWS 评分)。该评分在推导队列(Hosmer-Lemeshow 检验,P >.05)和外部验证队列(Hosmer-Lemeshow 检验,P >.05)中均具有良好的校准度。在推导队列(C 统计量为 0.859,95%置信区间为 0.776-0.945)和外部验证队列(C 统计量为 0.795,95%置信区间为 0.645-0.945)中,该评分均具有良好的区分能力。LAWS 评分是第一个能够预测 allo-HSCT 患者 ICH 后 30 天死亡率的评分系统。它在确定 allo-HSCT 患者在 ICH 诊断后早期死亡风险增加方面表现良好。我们预计,它将有助于对 allo-HSCT 患者进行风险分层,并为不同 LAWS 风险组患者制定个性化和新型干预措施的未来研究提供帮助。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d2/9153001/4d207577f8a5/advancesADV2021004349absf1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验